Intratumoral immunotherapy for melanoma

Cancer Immunology, Immunotherapy

Volumn 64, Issue 7, 2015, Pages 911-921

  Singh, Manisha ^a   Overwijk, Willem W ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

CIMT 2014; Immunoagonists; Immunotherapy; Intratumoral; Melanoma; Oncolytic viruses; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL VACCINE; CANCER VACCINE; CYTOKINE; CYTOKINE RECEPTOR AGONIST; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGIC AGENT; INTERLEUKIN 12; ONCOLYTIC VIRUS; RECOMBINANT HEAT SHOCK PROTEIN 70; STIMULATOR OF INTERFERON GENE AGONIST; SYNTHETIC IMMUNOAGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DISTANT METASTASIS; DRUG EFFICACY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MELANOMA; METASTATIC MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MELANOMA; ONCOLYTIC VIRUSES; T-LYMPHOCYTES;

EID: 84933180505     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1727-z     Document Type: Review

References (110)

1. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915. doi:10.1038/nm1100
2. van den Boorn JG, Hartmann G (2013) Turning tumors into vaccines: co-opting the innate immune system. Immunity 39:27–37. doi:10.1016/j.immuni.2013.07.011
3. Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW (2014) Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol 193:4722–4731. doi:10.4049/jimmunol.1401160
4. Nauts HC, Swift WE, Coley BL (1946) The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 6:205–216
5. Stewart JH, Levine EA (2011) Role of bacillus Calmette–Guerin in the treatment of advanced melanoma. Expert Rev Anticancer Ther 11:1671–1676. doi:10.1586/era.11.163
6. Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB (2012) Combined intralesional Bacille Calmette–Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716–720. doi:10.1097/CJI.0b013e31827457bd
7. Bast RC Jr, Zbar B, Borsos T, Rapp HJ (1974) BCG and cancer. N Engl J Med 290:1458–1469. doi:10.1056/NEJM197406272902605
8. Paterson AH, Willans DJ, Jerry LM, Hanson J, McPherson TA (1984) Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J 131:744–748
9. Akazawa T, Masuda H, Saeki Y et al (2004) Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 64:757–764
10. Freedman VH, Gorrell TE, Nathan CF, Copeland CS, Silverstein SC (1984) Bacillus Calmette–Guerin-activated murine macrophages kill syngeneic melanoma cells under strict anaerobic conditions. J Exp Med 160:94–107
11. Duda RB, Yang H, Dooley DD, Abu-Jawdeh G (1995) Recombinant BCG therapy suppresses melanoma tumor growth. Ann Surg Oncol 2:542–549
12. Udagawa M, Kudo-Saito C, Hasegawa G et al (2006) Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette–Guerin cell wall skeleton stimulation. Clin Cancer Res 12:7465–7475. doi:10.1158/1078-0432.CCR-06-1840
13. Hong EH, Chang SY, Lee BR, Pyun AR, Kim JW, Kweon MN, Ko HJ (2013) Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. Vaccine 31:1377–1384. doi:10.1016/j.vaccine.2013.01.006
14. Fox BA, Sanders KL, Chen S, Bzik DJ (2013) Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines. Trends Parasitol 29:431–437. doi:10.1016/j.pt.2013.07.001
15. Baird JR, Byrne KT, Lizotte PH et al (2013) Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol 190:469–478. doi:10.4049/jimmunol.1201209
16. Alemany R (2013) Viruses in cancer treatment. Clin Transl Oncol 15:182–188. doi:10.1007/s12094-012-0951-7
17. Ayala-Breton C, Barber GN, Russell SJ, Peng KW (2012) Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 23:484–491. doi:10.1089/hum.2011.146
18. Sinkovics JG, Horvath JC (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16:1–15
19. Maass G, Bogedain C, Scheer U et al (1998) Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther 9:1049–1059. doi:10.1089/hum.1998.9.7-1049
20. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30:658–670. doi:10.1038/nbt.2287
21. van Rikxoort M, Michaelis M, Wolschek M, Muster T, Egorov A, Seipelt J, Doerr HW, Cinatl J Jr (2012) Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS ONE 7:e36506. doi:10.1371/journal.pone.0036506
22. Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR (2011) Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol J. 8:22. doi:10.1186/1743-422X-8-22
23. Prestwich RJ, Errington F, Ilett EJ et al (2008) Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14:7358–7366. doi:10.1158/1078-0432.CCR-08-0831
24. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R (2011) VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther 19:150–158. doi:10.1038/mt.2010.225
25. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M (2005) Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 16:996–1005. doi:10.1089/hum.2005.16.996
26. Brun J, Mahoney DJ, Le Boeuf F, Lefebvre C, Sanaei CA, Falls T, McCart JA, Stojdl DF (2013) Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. Int J Cancer 132:726–731. doi:10.1002/ijc.27695
27. MacTavish H, Diallo JS, Huang B et al (2010) Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS ONE 5:e14462. doi:10.1371/journal.pone.0014462
28. Donnelly OG, Errington-Mais F, Steele L et al (2013) Measles virus causes immunogenic cell death in human melanoma. Gene Ther 20:7–15. doi:10.1038/gt.2011.205
29. Stanford MM, Shaban M, Barrett JW et al (2008) Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16:52–59. doi:10.1038/sj.mt.6300348
30. Prestwich RJ, Ilett EJ, Errington F et al (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15:4374–4381. doi:10.1158/1078-0432.CCR-09-0334
31. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B (2007) Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15:378–385. doi:10.1038/sj.mt.6300031
32. Andoniou CE, van Dommelen SL, Voigt V et al (2005) Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 6:1011–1019. doi:10.1038/ni1244
33. Edukulla R, Woller N, Mundt B et al (2009) Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 69:1448–1458. doi:10.1158/0008-5472.CAN-08-1160
34. Wongthida P, Diaz RM, Pulido C et al (2011) Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther 22:1343–1353. doi:10.1089/hum.2010.216
35. Bridle BW, Stephenson KB, Boudreau JE et al (2010) Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18:1430–1439. doi:10.1038/mt.2010.98
36. Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD (2004) Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 10:53–60
37. Hersey P, Gallagher S (2014) Intralesional immunotherapy for melanoma. J Surg Oncol 109:320–326. doi:10.1002/jso.23494
38. Galivo F, Diaz RM, Thanarajasingam U et al (2010) Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 21:439–450. doi:10.1089/hum.2009.143
39. Diaconu I, Cerullo V, Hirvinen ML et al (2012) Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 72:2327–2338. doi:10.1158/0008-5472.CAN-11-2975
40. Andarini S, Kikuchi T, Nukiwa M et al (2004) Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 64:3281–3287
41. Hayata K, Iwahashi M, Ojima T et al (2013) Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice. PLoS ONE 8:e53131. doi:10.1371/journal.pone.0053131
42. Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG (2013) The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther 21:348–357. doi:10.1038/mt.2012.204
43. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6:226ra32. doi:10.1126/scitranslmed.3008095
44. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6:409–422. doi:10.1038/sj.cgt.7700066
45. Senzer NN, Kaufman HL, Amatruda T et al (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763–5771. doi:10.1200/JCO.2009.24.3675
46. Goins WF, Huang S, Cohen JB, Glorioso JC (2014) Engineering HSV-1 vectors for gene therapy. Methods Mol Biol 1144:63–79. doi:10.1007/978-1-4939-0428-0_5
47. Dummer R, Rochlitz C, Velu T et al (2008) Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 16:985–994. doi:10.1038/mt.2008.32
48. Gupta P, Su ZZ, Lebedeva IV et al (2006) mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 111:596–628. doi:10.1016/j.pharmthera.2005.11.005
49. Ning J, Wakimoto H (2014) Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Front Microbiol 5:303. doi:10.3389/fmicb.2014.00303
50. Amos SM, Pegram HJ, Westwood JA et al (2011) Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother 60:671–683. doi:10.1007/s00262-011-0984-8
51. Lou Y, Liu C, Lizee G et al (2011) Antitumor activity mediated by CpG: the route of administration is critical. J Immunother 34:279–288. doi:10.1097/CJI.0b013e31820d2a05
52. Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, Ruers TJ, Adema GJ (2009) Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS ONE 4:e8368. doi:10.1371/journal.pone.0008368
53. Nierkens S, den Brok MH, Garcia Z et al (2011) Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res 71:6428–6437. doi:10.1158/0008-5472.CAN-11-2154
54. Marabelle A, Kohrt H, Sagiv-Barfi I et al (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123:2447–2463. doi:10.1172/JCI64859
55. Shirota Y, Shirota H, Klinman DM (2012) Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188:1592–1599. doi:10.4049/jimmunol.1101304
56. Kobayashi N, Hong C, Klinman DM, Shirota H (2013) Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. J Immunol 190:1882–1889. doi:10.4049/jimmunol.1201063
57. Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Langer R, Zugates GT, Anderson DG, Kornbluth RS (2009) Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. PLoS ONE 4:e7334. doi:10.1371/journal.pone.0007334
58. Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ (2011) Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin Cancer Res 17:3984–3992. doi:10.1158/1078-0432.CCR-10-3262
59. Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS (2010) A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol 185:7067–7076. doi:10.4049/jimmunol.1001137
60. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liau LM, Miller JF (2005) The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 175:1983–1990
61. Hayashi T, Chan M, Norton JT et al (2011) Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Res 21:66–75. doi:10.1097/CMR.0b013e328340ce6c
62. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G (2012) TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J Immunol 188:1583–1591. doi:10.4049/jimmunol.1102437
63. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 122:575–585. doi:10.1172/JCI61034
64. Tamada K, Chen L (2006) Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 55:355–362. doi:10.1007/s00262-005-0081-y
65. Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ (2013) Localized immunotherapy via liposome-anchored Anti-CD137+ IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res 73:1547–1558. doi:10.1158/0008-5472.CAN-12-3343
66. Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I (2012) Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther 20:1664–1675. doi:10.1038/mt.2012.56
67. Marabelle A, Kohrt H, Caux C, Levy R (2014) Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 20:1747–1756. doi:10.1158/1078-0432.CCR-13-2116
68. Marabelle A, Kohrt H, Levy R (2013) Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 19:5261–5263. doi:10.1158/1078-0432.CCR-13-1923
69. Fransen MF, Ossendorp F, Arens R, Melief CJ (2013) Local immunomodulation for cancer therapy: providing treatment where needed. Oncoimmunology 2:e26493. doi:10.4161/onci.26493
70. Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:674–678. doi:10.1038/nature07317
71. Gajewski TF, Corrales L (2015) New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev 26:175–178. doi:10.1016/j.cytogfr.2015.01.001
72. Nakhaei P, Hiscott J, Lin R (2010) STING-ing the antiviral pathway. J Mol Cell Biol 2:110–112. doi:10.1093/jmcb/mjp048
73. Burdette DL, Vance RE (2013) STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol 14:19–26. doi:10.1038/ni.2491
74. + T cell responses through CD8{alpha} + dendritic cells. J Exp Med 208:2005–2016. doi:10.1084/jem.20101159
75. Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461:788–792. doi:10.1038/nature08476
76. Woo SR, Fuertes MB, Corrales L et al (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41:830–842. doi:10.1016/j.immuni.2014.10.017
77. Woo SR, Corrales L, Gajewski TF (2015) The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 36:250–256. doi:10.1016/j.it.2015.02.003
78. Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, Watkins SC, Sarkar SN, Okada H (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199–1208. doi:10.1158/2326-6066.CIR-14-0099
79. Woodmansee C, Pillow J, Skinner RB Jr (2006) The role of topical immune response modifiers in skin cancer. Drugs 66:1657–1664
80. Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C (2009) Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo) 64:961–966. doi:10.1590/S1807-59322009001000005
81. Garland SM, Sellors JW, Wikstrom A, Petersen CS, Aranda C, Aractingi S, Maw RD, Imiquimod Study G (2001) Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts–results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS 12:722–729
82. Ooi T, Barnetson RS, Zhuang L, McKane S, Lee JH, Slade HB, Halliday GM (2006) Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol 154:72–78. doi:10.1111/j.1365-2133.2005.06932.x
83. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W (2003) The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149(Suppl 66):53–56
84. Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD (2011) Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29:5434–5442. doi:10.1016/j.vaccine.2011.05.061
85. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U (2008) Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 31:520–527. doi:10.1097/CJI.0b013e318174a4df
86. Carpentier A, Metellus P, Ursu R et al (2010) Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12:401–408. doi:10.1093/neuonc/nop047
87. Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB (2014) Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res 2:720–724. doi:10.1158/2326-6066.CIR-14-0024
88. Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B (2013) Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med 210:2803–2811. doi:10.1084/jem.20130678
89. Sondergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K (2010) Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. J Immunother 33:236–249. doi:10.1097/CJI.0b013e3181c0c1cb
90. Cha E, Daud A (2012) Plasmid IL-12 electroporation in melanoma. Hum Vaccin Immunother 8:1734–1738. doi:10.4161/hv.22573
91. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA (2012) Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18:1672–1683. doi:10.1158/1078-0432.CCR-11-3050
92. Yang RK, Kalogriopoulos NA, Rakhmilevich AL et al (2012) Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol 189:2656–2664. doi:10.4049/jimmunol.1200934
93. Pan J, Zhang M, Wang J, Wang Q, Xia D, Sun W, Zhang L, Yu H, Cao X (2005) Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response. J Cancer Res Clin Oncol 131:468–478. doi:10.1007/s00432-004-0651-y
94. Van der Jeught K, Joe PT, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, Escors D, Thielemans K, Breckpot K (2014) Intratumoral administration of mRNA encoding a fusokine consisting of IFN-beta and the ectodomain of the TGF-beta receptor II potentiates antitumor immunity. Oncotarget 5:10100–10113
95. Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16:35–48. doi:10.1089/hum.2005.16.35
96. Weide B, Eigentler TK, Pflugfelder A et al (2014) Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res 2:668–678. doi:10.1158/2326-6066.CIR-13-0206
97. Okano S, Kondoh H, Toshima T et al (2013) Fas-deficient fully allogeneic dendritic cells administered via an intratumoral injection route show efficient antitumor effects in murine models. Fukuoka Igaku Zasshi 104:15–26
98. Liu C, Lou Y, Lizee G et al (2008) Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118:1165–1175. doi:10.1172/JCI33583
99. Mito K, Sugiura K, Ueda K et al (2010) IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. Cancer Res 70:7093–7101. doi:10.1158/0008-5472.CAN-10-0600
100. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S (2006) Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 36:3371–3380. doi:10.1002/eji.200636053
101. Shevtsov MA, Kim AV, Samochernych KA, Romanova IV, Margulis BA, Guzhova IV, Yakovenko IV, Ischenko AM, Khachatryan WA (2014) Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther 7:1071–1081. doi:10.2147/OTT.S62764
102. Galili U (2011) Conversion of tumors into autologous vaccines by intratumoral injection of alpha-Gal glycolipids that induce anti-Gal/alpha-Gal epitope interaction. Clin Dev Immunol. doi:10.1155/2011/134020
103. Doukas J, Rolland A (2012) Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther 19:811–817. doi:10.1038/cgt.2012.69
104. Sandin LC, Eriksson F, Ellmark P, Loskog AS, Totterman TH, Mangsbo SM (2014) Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 3:e27614. doi:10.4161/onci.27614
105. Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P (2007) Intratumoral injection of IL-12 plasmid DNA-results of a phase I/IB clinical trial. Cancer Gene Ther 14:717–723. doi:10.1038/sj.cgt.7701064
106. Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R (2008) Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res 18:104–111. doi:10.1097/CMR.0b013e3282f702cf
107. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718–730. doi:10.1245/s10434-009-0809-6
108. Khorana AA, Rosenblatt JD, Sahasrabudhe DM et al (2003) A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 10:251–259. doi:10.1038/sj.cgt.7700568
109. Rochlitz C, Dreno B, Jantscheff P et al (2002) Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 9:289–295. doi:10.1038/sj.cgt.7700441
110. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S (2000) Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89:2646–2654